DDrare: Database of Drug Development for Rare Diseases

109. 非典型溶血性尿毒症症候群
［臨床試験数：95，薬物数：27（DrugBank：5），標的遺伝子数：2，標的パスウェイ数：9］

Searched query = "Atypical hemolytic uremic syndrome", "aHUS"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = ALN-CC5; ALXN1210; Anti-C5 antibody; CCX168; COVERSIN; Cemdisiran; Coversin; ECULIZUMAB; Eculizumab; Fc- and CDR-modified humanised monoclonal antibody against C5; IgG2/4?; MASP-2 antibody; OMS00620646, OMS620646, MASP-2 Antibody; OMS721; OMS721 100 mg/ml Injection solution, OMS00620646, OMS620646, MASP-2 Antibody; OMS721 185 mg/ml Injection solution, OMS00620646, OMS620646, MASP-2 Antibody; OMS721 Drug Product 185 mg/mL; Other: Eculizumab; RVA576; RVA576 (COVERSIN); RVA576 (Coversin); Ravulizumab; SOLIRIS; SOLIRIS - 300 MG CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO 1 FLACONCINO (VETRO) 30 ML (10 MG/ML); SOLIRIS 300 mg concentrado para solución para perfusión; Solaris; Soliris

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02464891 (ClinicalTrials.gov)	June 4, 2015	26/5/2015	Complement Inhibition in aHUS Dialysis Patients	An Open-label Phase 2 Study to Assess the Effect of C5aR Antagonist Therapy by CCX168 Oral Administration on ex Vivo Thrombus Formation and Disease Activity in ESRD Patients With Atypical Hemolytic Uremic Syndrome	Atypical Hemolytic Uremic Syndrome	Drug: CCX168	Mario Negri Institute for Pharmacological Research	ChemoCentryx	Terminated	18 Years	N/A	All	6	Phase 2	Italy
2	EUCTR2014-004261-24-IT (EUCTR)	08/05/2015	25/09/2018	PROPOSAL OF STUDY TO DETERMINE IF THE ORAL ADMINISTRATION OF CCX168 INHIBITS THE ACTIVITY 'COMPLEMENT AND THE FORMATION OF CLOTS IN PATIENTS WITH ATYPICAL HEMOLYTIC UREMIC SYNDROME IN DIALYSIS	AN OPEN-LABEL PHASE 2 STUDY TO ASSESS THE EFFECT OF C5AR ANTAGONIST THERAPY BY CCX168 ORAL ADMINISTRATION ON EX VIVO THROMBUS FORMATION AND DISEASE ACTIVITY IN ESRD PATIENTS WITH ATYPICAL HEMOLYTIC UREMIC SYNDROME (ACCESS Study) - Complement inhibition in aHUS dialysis patients	Atypical Hemolytic Uremic Syndrome MedDRA version: 20.0;Level: LLT;Classification code 10019515;Term: Hemolytic uremic syndrome;System Organ Class: 100000004851;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]	Product Name: CCX168 Product Code: CCX168	IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI	NULL	Not Recruiting			Female: yes Male: yes	10	Phase 2	Italy

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT02464891
(ClinicalTrials.gov)

June 4, 2015

26/5/2015

Complement Inhibition in aHUS Dialysis Patients

An Open-label Phase 2 Study to Assess the Effect of C5aR Antagonist Therapy by CCX168 Oral Administration on ex Vivo Thrombus Formation and Disease Activity in ESRD Patients With Atypical Hemolytic Uremic Syndrome

Atypical Hemolytic Uremic Syndrome

Drug: CCX168

Mario Negri Institute for Pharmacological Research

ChemoCentryx

Terminated

18 Years

N/A

All

Phase 2

Italy

EUCTR2014-004261-24-IT
(EUCTR)

08/05/2015

25/09/2018

PROPOSAL OF STUDY TO DETERMINE IF THE ORAL ADMINISTRATION OF CCX168 INHIBITS THE ACTIVITY 'COMPLEMENT AND THE FORMATION OF CLOTS IN PATIENTS WITH ATYPICAL HEMOLYTIC UREMIC SYNDROME IN DIALYSIS

AN OPEN-LABEL PHASE 2 STUDY TO ASSESS THE EFFECT OF C5AR ANTAGONIST THERAPY BY CCX168 ORAL ADMINISTRATION ON EX VIVO THROMBUS FORMATION AND DISEASE ACTIVITY IN ESRD PATIENTS WITH ATYPICAL HEMOLYTIC UREMIC SYNDROME (ACCESS Study) - Complement inhibition in aHUS dialysis patients

Atypical Hemolytic Uremic Syndrome
MedDRA version: 20.0;Level: LLT;Classification code 10019515;Term: Hemolytic uremic syndrome;System Organ Class: 100000004851;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]

Product Name: CCX168
Product Code: CCX168

IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI

NULL

Not Recruiting

Female: yes
Male: yes

Phase 2

Italy